DEA OKs Company for Bulk Marijuana Making Madness
Published Date: 2/27/2025
Notice
Summary
Groff NA Hemplex LLC wants to become a big-time producer of marijuana and related substances for research. If you’re a registered manufacturer or interested party, you can share your thoughts or ask for a hearing by April 28, 2025. This move helps support scientific studies and keeps the process open and fair.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
New Schedule I Research Supplier Applied
On September 30, 2024, Groff NA Hemplex LLC (2218 South Queen Street, York, Pennsylvania 17402) applied to register as a bulk manufacturer of Marihuana Extract (code 7350), Marihuana (code 7360), and Tetrahydrocannabinols (code 7370), all Schedule I. The application seeks authorization to conduct cultivation activities to bulk manufacture those substances for internal use and for sale to federally registered research investigators only. Interested registered manufacturers or applicants may submit comments or request a hearing on or before April 28, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-03169, Agency Information Collection Activities; Submission to the Office of Management and Budget; Administrative Procedures for U.S. Fish and Wildlife Service Financial Assistance Programs
The U.S. Fish and Wildlife Service is renewing its paperwork for financial help programs without making any changes. This affects anyone applying for or managing these grants, and they’re asking for public comments by March 31, 2025. No new costs or deadlines are added, just a smooth continuation of current rules.
Next: 2025-03171, Marqeta, Inc.
Marqeta, Inc. asked the SEC to officially say it’s mainly a tech company that makes payment card platforms—not an investment company. This means Marqeta won’t have to follow some investment rules, helping it focus on its payment services. If no one asks for a hearing by March 21, 2025, the SEC will likely approve this change.